Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation;Proteus mirabilis izolovaný z močí, jeho rezistence k antibiotikům a tvorba biofilmu

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 17, Issue 3, 2011, Pages 81-85

  Černohorská, Lenka ^a   Chvilova E ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Biofilm; Proteus mirabilis; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFALOTIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; OXOLINIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BIOFILM; DISK DIFFUSION; NONHUMAN; PROTEUS MIRABILIS; URINALYSIS; URINARY TRACT INFECTION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHYSIOLOGY; PROTEUS INFECTION; URINE;

BIOFILMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEUS INFECTIONS; PROTEUS MIRABILIS; URINARY TRACT INFECTIONS; URINE;

EID: 79960903916     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Weber G, Riesenberg K, Schlaeffer F, et al. Changing trends in frequency and antimicrobial resistance of urinary pathogens in outpatient clinics and a hospital in Southern Israel, 1991-1995. European Journal of Clinical Microbiology & Infectious Diseases. 1997;16(11):834-838.
2. Gorman SP, Jones DS. Biofilm complications of urinary tract devices. In: Wilson M, Devine D (eds). Medical Implications of Biofilms. Cambridge: Cambridge University Press; 2003. s. 136-170. ISBN 0-521-81240-2.
3. Holá V, Růžička F. Biofilmové infekce močových katétrů. Epidemiol Mikrobiol Imunol. 2008;57(2):47-52.
4. Hryniewicz K, Szczypa K, Sulikowska A, et al. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. Antimicrob Chemother. 2001;47(6):773-780.
5. Miragliotta G, Di Pierro MN, Miragliotta L, Mosca A. Antimicrobial resistance among uropathogens responsible for community-acquired urinary tract infections in an Italian community. J Chemother. 2008;20(6):721-727.
6. Nucleo E, Fugazza G, Migliavacca R, et al. Differences in biofilm formation and aggregative adherence between β-lactam susceptible and β-lactamases producing Proteus mirabilis clinical isolates. New microbiologica. 2010;33:37-45.
7. Jones BD, Mobley HL. Genetic and biochemical diversity of ureases of Proteus, Providencia, and Morganella species isolated from urinary tract infectionInfect Immun. 1987;5592198-2203. (Pubitemid 17139303)
8. Mobley HLT, Belas R. Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends in Microbiology. 1995;3(7):280-284.
9. Zhao H, Thompson RB, Lockatell V, Johnson DE, Mobley HL. Use of green fluorescent protein to assess urease gene expression by uropathogenic Proteus mirabilis during experimental ascending urinary tract infection. Infect Immun. 1998; 66(1):330-335.
10. Broomfield RJ, Morgan SD, Khan A, Stickler DJ. Crystalline bacterial biofilm formation on urinary catheters by urease-producing urinary tract pathogens: a simple method of control. J Med Microbiol 2009;58(10):1367-1375.
11. Černohorská L, Andrysík T. Detekce β-laktamáz typu AmpC u gramnegativních bakterií izolovaných z moče. Epidemiol Mikrobiol Imunol. 2008;57(4):141-146.
12. Hrabák J, Vaniš V, Bergerová T, Urbáš ková P. Průkaz β-laktamáz širokého spektra (ESBL) a typu AmpC u enterobakterií. Zprávy CEM (SZÚ Praha). 2007; 16: 31-36.
13. Kolář M, Urbánek K, Látal M. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents. 2001;17:357-363.
14. Kolář M, Urbánek K, Lochmannová J. Výchozí zdroje racionální antibiotické léčby bakteriálních infekcí. Prakt Lékáren. 2006;1:20-23.
15. Černohorská L, Sláviková P. Pseudomonas aeruginosa, její rezistence i vybraným antibiotikům a tvorba biofilmu u kmenů izolovaných od pacientů s infekcí močových cest. Epidemiol Mikrobiol Imunol. 2009;58(4):154-157.
16. Černohorská L, Votava M. Biofilm a jeho význam v lékařské mikrobiologii. Epidemiol Mikrobiol Imunol. 2002;514:161-164. (Pubitemid 35378866)
17. Hoyle BD, Costerton JW. Bacterial resistance to antibiotics: the role of biofilms. Prog Drug Res. 1991;37:91-105.
18. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilmsThe Lancet. 2001;3589276 135-138. (Pubitemid 32709857)
19. Urbášková P. Vybrané metody. Praha: IPVZ, 1996, 32 s.
20. Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun. 1982;37(1):318-326.
21. Christensen GD, Simpson WA, Younger JJ, et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol. 1985;22(6): 996-1006.
22. Luzzaro F, Perilli M, Amicosante G, et al. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of [beta]-lactam/[beta]-lactamase inhibitor combinations. International Journal of Antimicrobial Agents. 2001;17(2):131-135.
23. Wu L, Wu H, Chung J, et al. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 [beta]-lactamases at 2 hospitals in TaiwanDiagnostic Microbiology and Infectious Disease. 2006;542:89-94. (Pubitemid 43176596)
24. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. ProcNallAcad. Sci. U.S.A. 2007; 10427:11197-11202. (Pubitemid 47175118)
25. Struble K, Bronze MS, Jackson RL, Gonzales G. Proteus infections, updated: July 31, 2009. Available from: http://emedicine.medscape.com/article/ 226434-over-view.